Congress removes red tape blocking addiction treatment—but states may find new ways to restrict it

What it does

This bill removes prior authorization requirements and dosage limits for medication-assisted treatment (MAT) drugs for opioid use disorder under Medicaid, requiring states to cover at least one formulation of each approved MAT drug without these restrictions. It also directs a federal commission to study how utilization management controls affect access to addiction treatment.

Why we flagged it

The bill removes administrative barriers (prior authorization, dosage limits) to increase access to evidence-based addiction treatment. It is deregulatory in nature but aimed at expanding treatment access rather than reducing safety oversight.

What the text implies

• Removal of prior authorization may increase overall Medicaid spending on MAT drugs, potentially shifting costs to state budgets and federal matching funds.
• States retain formulary control, meaning they can still limit which specific drugs are covered—the bill only prevents prior authorization and dosage limits on covered drugs.
• The MACPAC study may reveal that other state-level barriers (e.g., counseling requirements, psychological screening) remain significant obstacles even after this bill passes.
• Pharmaceutical manufacturers of MAT drugs (buprenorphine, methadone, naltrexone formulations) benefit from reduced administrative friction, potentially increasing volume and market share.

Who it affects

Removing administrative barriers to evidence-based addiction treatment directly benefits patients with opioid use disorder by reducing delays in accessing life-saving medications. Faster access to MAT improves health outcomes and reduces overdose deaths, a documented public health crisis.

Who stands to gain

• Pharmaceutical manufacturers of medication-assisted treatment drugs
• Opioid treatment programs and addiction medicine clinics
• Medicaid managed care organizations (reduced administrative burden)

Named in the bill

Medicaid, Social Security Act Section 1905, Social Security Act Section 1927, MACPAC (Medicaid and CHIP Payment and Access Commission), HHS (Department of Health and Human Services), State Medicaid agencies, Buprenorphine, Methadone, Naltrexone, BMY (Bristol Myers Squibb), GH (Guardant Health), PFE (Pfizer) — and 2 more

Where it stands

1 cosponsor: 1 Republicans.

• Dec 17, 2025 — Introduced · Congress.gov: “Introduced in Senate”
• Dec 17, 2025 — Referred to Senate Committee on Finance · Congress.gov: “Read twice and referred to the Committee on Finance”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

5 lobbying clients named this bill on 6 disclosure filings across 3 quarters, Dec 2025 to Jun 2026. Those filings disclosed $1,646,750 in lobbying spend. A filing names 10 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 78% of bills with at least one filing.

Maggie Hassan, the sponsor, reported $608,285 in PAC receipts in the 2026 cycle.

• American Academy of Family Physicians — $1,048,023 on 1 filing
• American College of Emergency Physicians — $468,727 on 1 filing
• Tobacco-free Kids Action Fund Fka Global Health Advocacy Incubator (ghai) — $90,000 on 2 filings
• American Association for the Treatment of Opioid Dependence — $20,000 on 1 filing
• Kelley Drye & Warren Llp Obo Tobacco-free Kids Action Fund — $20,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.